Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

A woman demands Pfizer "free the vaccine" at a March 11, 2021 demonstration outside the company's world headquarters in New York City. (Photo: Erik McGregor/LightRocket via Getty Images)

A woman demands Pfizer "free the vaccine" at a March 11, 2021 demonstration outside the company's world headquarters in New York City. (Photo: Erik McGregor/LightRocket via Getty Images)

As Coronavirus Ravages India, Senate Dems Urge US Pharma Firms to Share Vaccine Tech

"Addressing the spread of Covid-19 in India is critical," the senators wrote in a letter imploring drugmaker CEOs to take steps to "drastically expand vaccine development and access." 

Brett Wilkins

As Covid-19 hospitalizations and deaths continue to soar in India, a group of Democratic U.S. senators on Wednesday sent letters to three Big Pharma CEOs urging them to expand global vaccine access by sharing technology and by lifting intellectual property barriers to allow countries to locally produce vaccines.

"Increasing Covid-19 vaccinations in India is urgently needed to reduce human suffering and prevent unnecessary deaths. It could also help halt the spread of coronavirus variants that could prolong the pandemic across the globe."
—Senators' letter

"Covid-19 has infected over 148 million people and killed over three million globally, with hundreds of thousands of new cases and thousands of deaths being reported daily," write Democratic Sens. Elizabeth Warren (Mass.), Ed Markey (Mass.), Tammy Baldwin (Wis.), Jeff Merkley (Ore.), and Chris Murphy (Conn.) to the CEOs of Pfizer, Moderna, and Johnson & Johnson.

The senators warn that although these "and other companies have developed safe and effective Covid-19 vaccines, the uncontrolled spread of coronavirus poses significant risks to global vaccination efforts. As the virus proliferates, it evolves, increasing the risk of a variant developing that renders vaccinations ineffective." 

"Though wealthier countries, including the United States, have successfully secured vaccines and have made significant strides in vaccinating their populations, many middle- and lower-income nations have less access to vaccine doses," the letter continues. "A recent study estimates that unequal global vaccine distribution could result in a gross domestic product loss of $1.2 trillion annually for the global economy."

The senators highlight the acute crisis in India, where over 360,000 new coronavirus cases—the most ever recorded in a country in a single day during the pandemic—and 3,293 deaths were reported Wednesday as the nation passed the grim milestone of 200,000 Covid-19 fatalities. 

Although noting that India is a "major producer" of the Oxford/AstraZeneca coronavirus vaccine, and that it has exported over 66 million doses this year, the senators write that "it is still struggling to vaccinate people quickly enough to quell the outbreak." 

"Addressing the spread of Covid-19 in India is critical," they assert, adding that there are steps the pharma giants can take "to increase global vaccine access."

"Increasing Covid-19 vaccinations in India is urgently needed to reduce human suffering and prevent unnecessary deaths," the letter states. "It could also help halt the spread of coronavirus variants that could prolong the pandemic across the globe."

Sharing technology, "such as vaccine recipes and manufacturing information," could "drastically expand vaccine development and access," it adds. 

"This technology transfer could take place voluntarily, underpinned by open, non-exclusive, and transparent agreements done in collaboration with the World Health Organization," the senators argue, pointing to the WHO's Covid-19 Technology Access Pool (C-TAP) and its mRNA vaccine technology transfer hub, through which the United Nations agency and its partners are "seeking to expand the capacity of low- and middle-income countries to produce Covid-19 vaccines and scale up manufacturing to increase global access to these critical tools." 

The lawmakers also note that experts have "called for the U.S. to support the temporary waiver of some Trade-Related Aspects of Intellectual Property Rights (TRIPS) rules proposed by India and South Africa at the World Trade Organization (WTO), which would temporarily lift certain intellectual property barriers and allow countries to locally manufacture Covid-19 diagnostics, treatments, and vaccines." 

Earlier this month, Sen. Bernie Sanders (I-Vt.) led a group of 10 senators including Baldwin, Markey, Merkley, Murphy, and Warren in calling on President Joe Biden to back a global effort for a temporary WTO TRIPS waiver. 

Wednesday's letter asks each of the companies if they have taken any of these or other steps, and if not, why. 

"Now is the time to use every single opportunity in every single corner of the world. These companies should make deals with as many countries as possible."
—Abdul Muktadir,
Bangladeshi pharma CEO 

The pharmaceutical industry has dismissed efforts to permit the sharing of intellectual property to create generic coronavirus vaccines, claiming that some countries lack the facilities in which to safely manufacture them. Powerful global players like billionaire businessman and philanthropist Bill Gates, whose software fortune is largely dependent upon stringent intellectual property protection laws, have echoed this assertion—which factory owners around the world roundly refute.

"Now is the time to use every single opportunity in every single corner of the world," Abdul Muktadir, CEO of the Bangladeshi pharmaceutical company Incepta, told the Washington Post. Muktadir said he emailed executives at Moderna, Johnson & Johnson, and Novavax to offer help—he said his company can produce as many as 800 million vaccine doses per year—but none of them wrote back.

"These companies should make deals with as many countries as possible," he said. 


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

14-Year-Old Indigenous Land Defender Killed in Colombia

"We condemn the killing of Breiner David Cucuñame!" says Fridays for Future MAPA. "We join the calls for justice and stand in solidarity with the environmental defenders in Colombia and across the world!"

Jessica Corbett ·


Catching Up With Progressives, Biden Provides N95s Nationwide

Sen. Bernie Sanders, who introduced the Masks for All Act in July 2020, called the move "a good first step."

Julia Conley ·


Bank Blocks Donations Supporting Cuban Effort to Vaccinate World

"A European bank, established in the Netherlands, has decided to put the interests of the U.S. government above the lives of millions of people."

Kenny Stancil ·


450+ Climate Scientists Demand PR Industry Drop Fossil Fuel Clients

"To put it simply, advertising and public relations campaigns for fossil fuels must stop," states an open letter to ad agencies and major firms.

Andrea Germanos ·


100+ Ultra-Rich People Warn Fellow Elites: 'It's Taxes or Pitchforks'

"History paints a pretty bleak picture of what the endgame of extremely unequal societies looks like," reads an open letter signed by millionaires and billionaires calling for higher taxes on people like themselves.

Jake Johnson ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo